As billions of dollars are committed to tackling malaria and HIV in Africa yearly, one disease is killing more people than ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

HIV/AIDS cases and deaths have gone up dramatically in the Philippines in the last decade, even though there are drugs to ...

In 2025, public health concerns focus on the threats of bird flu, malaria, HIV, and tuberculosis. H5N1 influenza poses a ...

Currently, lenacapavir is approved in the US and other countries for the treatment of adults with drug-resistant HIV. But in ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

Three men sought help at clinics or emergency rooms in Los Angeles County over a three-month period this year, each reporting ...

Super lice do not look any different from normal lice. They’re identified by their resistance to common treatment. With proper over-the-counter treatment, head lice can be treated. Super lice ...

Gilead Sciences is seeking approval from the USFDA and the World Health Organization (WHO) for a global rollout of its injectable drug version. A new variant of Lenacapavir, a drug used to treat ...

A rash may occur after you contract HIV. It commonly appears on the face and chest but can also appear in other places. Medications used to treat HIV as well as certain infections may also cause ...

Lenacapavir is already approved for use as a treatment for multi-drug resistant HIV, costing around $42,250 for the first year of therapy in the United States. Clinical trials this year showed it ...

Hope abounds that the antiretroviral drug already approved in a number of countries to help treat adults with multidrug-resistant HIV, could dramatically speed up the fight against the virus ...